Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gilbert

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Lancet. Infectious Diseases|June 2, 2012
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, et al.
Plos One|April 21, 2010
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmissionVladimir Novitsky, Rui Wang, Hermann Bussmann, et al.
Elife|September 17, 2021
Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1Shida Shangguan, Philip K Ehrenberg, Aviva Geretz, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Journal of Virology|May 10, 2013
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesPinghuang Liu, Nicole L Yates, Xiaoying Shen, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Lancet. Infectious Diseases|June 2, 2012
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144Merlin L Robb, Supachai Rerks-Ngarm, Sorachai Nitayaphan, et al.
Plos One|April 21, 2010
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmissionVladimir Novitsky, Rui Wang, Hermann Bussmann, et al.
Elife|September 17, 2021
Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1Shida Shangguan, Philip K Ehrenberg, Aviva Geretz, et al.
Ebiomedicine|January 20, 2015
Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesSusan Zolla-Pazner, Paul T Edlefsen, Morgane Rolland, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Clinical and Vaccine Immunology : CVI|September 26, 2014
Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participantsSharon E Frey, Laurence Peiperl, M Juliana McElrath, et al.
Nature Biotechnology|May 26, 2015
COMPASS identifies T-cell subsets correlated with clinical outcomesLin Lin, Greg Finak, Kevin Ushey, et al.
Journal of Virology|May 10, 2013
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesPinghuang Liu, Nicole L Yates, Xiaoying Shen, et al.
JAMA Network Open|January 23, 2023
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Jessica E Long, Yunda Huang, et al.
Plos One|October 3, 2013
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trialRaphael Gottardo, Robert T Bailer, Bette T Korber, et al.
Pageof 10